CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, a neuromodulation device that enhance symptoms for patients with heart failure by delivering electrical pulses to baroreceptors. It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

CVRx Inc.

In a report released today, William Plovanic from Canaccord Genuity reiterated a Buy rating on CVRx, with a price target of $11.00. According to Ti...

CVRx (CVRX) Gets a Buy from Canaccord Genuity

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on CVRx (CVRX – Research Report) and Lifecore Biomedica...

Market Cap	$220.43M	P/E Ratio	N/A
52W High	$18.55	52W Low	$4.30
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	14.0%	52W Position	29.1%
Overall Score	44	Value Score	55
Quality Score	42	Technical Score	36

EPS Current Est	$-2.01	EPS Next Est	$-1.84
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CVRX	$8.45	+0.36%	154.81K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CVRX	$8.45	+0.4%	154.81K
3
4
5
6

CVRX

CVRX

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get CVRx Inc. Data in Excel

Get CVRx Inc. Data in Excel